Market Place
Sourcing Support
UCB Acquires IMIDomics` Patient Insights Unit
01 May 2026 //
PHARMIWEB
UCB Issues Convening Notice For 2026 Shareholders` Meeting
27 Mar 2026 //
GLOBENEWSWIRE
UCB Reaps The Rewards Of Fast-Growing Bimzelx
27 Feb 2026 //
FIERCE PHARMA
UCB Showcase Epilepsy Portfolio Advancements at Epilepsy Congress
30 Aug 2025 //
PR NEWSWIRE
UCB`s Fintepla shows potential to treat a 3rd epilepsy disorder
28 Jun 2025 //
FIERCE PHARMA
UCB Reports Positive Ph3 GEMZ Results in CDKL5 Disorder
27 Jun 2025 //
PR NEWSWIRE
UCB & Domino Lab modernize statistical computing in Life Science
19 May 2025 //
PR NEWSWIRE
Dr. Pimple Popper joins UCB hidradenitis suppurativa campaign
24 Apr 2025 //
FIERCE PHARMA
UCB presents latest neurology research at AAN meeting 2025
03 Apr 2025 //
PR NEWSWIRE
Grove AI Adds Former Executives to Advisory Board
02 Apr 2025 //
GLOBENEWSWIRE
UCB Shareholders` Meeting Notice 2025
21 Mar 2025 //
GLOBENEWSWIRE
New data on therapy for thymidine kinase 2 deficiency at MDA 2025
19 Mar 2025 //
PR NEWSWIRE
UCB-Novartis Parkinson`s asset fails to improve symptoms in ph. 2
16 Dec 2024 //
FIERCE BIOTECH
UCB Presents Data On Epilepsy At AES 2024 Annual Meeting
06 Dec 2024 //
PR NEWSWIRE
CBC Group Complete Strategic Acquisition Of UCB’s Product Portfolio
29 Nov 2024 //
PR NEWSWIRE
UCB Presents Epilepsy Research at AES Annual Meeting
26 Nov 2024 //
PR NEWSWIRE
Roche tosses out $120M tau prospect, returning rights to UCB
23 Oct 2024 //
FIERCE BIOTECH
Argenx isn`t sweating over Vyvgart competitors: exec
10 May 2024 //
FIERCE PHARMA
UCB: Neurology Developments At AAN 2024
12 Apr 2024 //
PR NEWSWIRE
UCB debuts first campaign for psoriasis drug Bimzelx during Oscars
12 Mar 2024 //
ENDPTS
UCB departs industry trade group BIO, following Pfizer`s exit late last year
04 Jan 2024 //
ENDPTS
UCB presents new data about the real-world experience of FINTEPLA
02 Dec 2023 //
PR NEWSWIRE
Post Hoc Analysis Showed CIMZIA Resulted in Meaningful Efficacy for RA Patients
11 Nov 2023 //
PR NEWSWIRE
UCB Presents New Five-Year Data on BIMZELX in Ankylosing Spondylitis
10 Nov 2023 //
PR NEWSWIRE
UCB presents latest data from generalized myasthenia gravis portfolio
01 Nov 2023 //
PR NEWSWIRE
NAYZILAM Results Published in `Epilepsy & Behavior`
31 Oct 2023 //
PR NEWSWIRE
UCB wins FDA approvals in plaque psoriasis and gMG
19 Oct 2023 //
ENDPTS
UCB announces U.S. FDA approval of ZILBRYSQ for myasthenia gravis
17 Oct 2023 //
PR NEWSWIRE
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa
13 Oct 2023 //
PR NEWSWIRE
UCB announces U.S. availability of RYSTIGGO for the treatment of gMG
21 Jul 2023 //
PR NEWSWIRE
Veeva, UCB link to leverage digital tools in clinical trials
24 May 2023 //
FIERCE BIOTECH
UCB and Ariceum sign a Strategic Research Collab to Discover New Modalities
10 May 2023 //
PR NEWSWIRE
UCB Showcases Strength and Depth of Neurology Portfolio at 75th (AAN) Meeting
20 Apr 2023 //
PR NEWSWIRE
UCB`s second shot at Neupro patent validation fails on appeal
13 Apr 2023 //
FIERCE PHARMA
UCB, Aitia Enter Strategic Drug Discovery Alliance in Huntington`s Disease
16 Mar 2023 //
CONTRACT PHARMA
UCB`s bimekizumab granted FDA 6-month review period
29 Dec 2022 //
FIERCE PHARMA
UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab
23 Dec 2022 //
PIPELINEREVIEW
Praxis ends year on high with $100M biobucks UCB deal
15 Dec 2022 //
FIERCEBIOTECH
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
13 Dec 2022 //
GLOBENEWSWIRE
UCB`s psoriasis drug proves itself in hidradenitis suppurativa
10 Dec 2022 //
FIERCEPHARMA
The Lancet Publishes Results from Bimekizumab PIII Study in Psoriatic Arthritis
07 Dec 2022 //
PRNEWSWIRE
UCB presents latest data from generalized myasthenia gravis portfolio
22 Sep 2022 //
UCB
EMA ccepts Marketing Authorization Applications for Bimekizumab
20 Sep 2022 //
PHARMIWEB
China suspends UCB`s anti-seizure drug Keppra after manufacturing issue
25 Aug 2022 //
FIERCEPHARMA
UCB pens multiple collabs to boost cluster seizure awareness
23 Aug 2022 //
FIERCEPHARMA
UCB lowers 2022 profit expectations amid rising costs
24 Jun 2022 //
FIERCEPHARMA
Positive MHRA decision for Briviact
23 Jun 2022 //
PHARMATIMES
Roswell Biotechnologies Forges Early Research Collaboration with UCB
08 Jun 2022 //
PRNEWSWIRE
NICE recommends UCB’s Fintepla for Dravet syndrome
01 Jun 2022 //
PHARMATIMES
Purchase of UCB shares
23 May 2022 //
GLOBENEWSWIRE
UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies
23 May 2022 //
PRNEWSWIRE
First Presentations of Phase 3 Data for Bimekizumab in Axial Spondyloarthritis
23 May 2022 //
PRNEWSWIRE
FDA rejects UCB’s psoriasis therapy bimekizumab
14 May 2022 //
PHARMAPHORUM
UCB details positive pivotal data for myasthenia gravis
10 May 2022 //
ENDPTS
Ampersand Health and UCB partner in new arthritis initiative
13 Apr 2022 //
PHARMATIMES
UCB Showcases Strength of Broad Neurology Portfolio at 74th AAN
01 Apr 2022 //
PRNEWSWIRE
UCB takes on Jazz in severe epilepsy with new Fintepla label approval
29 Mar 2022 //
PHARMAPHORUM
New Long-Term Complete Skin Clearance Data for Bimekizumab in Plaque Psoriasis
26 Mar 2022 //
PRNEWSWIRE
UCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022
25 Mar 2022 //
GLOBENEWSWIRE
UCB Completes Acquisition of Zogenix, Inc.
07 Mar 2022 //
PRNEWSWIRE
